Irvine Scientific launches new feed media to maximize productivity in large-scale bioproduction
BalanCD CHO Feed 4 is a chemically-defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells.
Irvine Scientific has launched BalanCD CHO Feed 4, a chemically defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells. When paired with BalanCD CHO Growth A in fed-batch culture systems, up to 20 million viable cells/mL, and antibody titer up to 6g/ L can be achieved.
Recent developments in cell line engineering have resulted in cell lines capable of reaching higher cell densities and productivity rates. To achieve their full production potential these cell lines need nutrient-rich media; however these feeds can be difficult to dissolve and require complicated time-consuming preparation protocols. BalanCD CHO Feed 4 is designed and formulated to prepare easily using a simplified hydration procedure that does not require pH adjustments. BalanCD CHO Feed 4 maintains pH stability in culture and is designed to support growth while minimizing the production of metabolites that adversely affect titer levels; this results in process consistency, significantly higher protein production and protein quality.
“Surveys of large-scale culture media end-users identify time and effort required for mixing powdered media as a top concern. By applying our expertise at media development and formulation we are able to deliver a product that provides performance, flexibility and ease-of-use that facilitates a more robust process.” said Dr Jessie H.-T. Ni, Chief Scientific Officer of Irvine Scientific. “This new Feed is a significant addition to our BalanCD CHO platform that is designed to streamline the development and scale-up process to help our customers get to market faster.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...